Active Trials - Enrolling	
Gilead 95 (Crohn's Disease)	Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease
Gilead 96 (Crohn's Disease)	A Long Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease
Trident (Crohn's Disease)	A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER PROTOCOL TO EVALUATE THE SAFETY AND EFFICACY OF JNJ-64304500 IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
Power (Crohn's Disease	A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS RE-INDUCTION THERAPY WITH USTEKINUMAB IN PATIENTSWITH MODERATELY TO SEVERELY ACTIVE CROHN¿S DISEASE PATIENT OPTIMIZATION WITH USTEKINUMAB RE-INDUCTION
Galaxi (Crohn's Disease)	A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease
Aurora (Ulcerative Colitis)	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects with Moderately to Severely Active Ulcerative Colitis.
Quasar (Ulcerative Colitis)	A PHASE 2B/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER PROTOCOL TO EVALUATE THE EFFICACY AND SAFETY OF GUSELKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Rhea (Ulcerative Colitis)	A PHASE 2B/3 MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED, PARALLEL-GROUP SET OF STUDIES TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND MAINTENANCE THERAPY WITH TD-1473 IN SUBJECTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
AbbVie	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABT-494 FOR INDUCTION AND MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (M14-234)
AbbVie	MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MAINTENANCE AND LONG-TERM EXTENSION STUDY OF THE EFFICACY AND SAFETY OF UPADACITINIB (ABT-494) IN SUBJECTS WITH CROHN'S DISEASE WHO COMPLETED THE STUDIES M14-431 OR M14-433(M14-430)

AbbVie	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY OF THE EFFICACY AND SAFETY OF UPADACITINIB (ABT-494) IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE INADEQUATELY RESPONDED TO OR ARE INTOLERANT TO BIOLOGIC THERAPY (M14-431)
AbbVie	MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY OF THE EFFICACY AND SAFETY OF UPADACITINIB (ABT-494) IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE INADEQUATELY RESPONDED TO OR ARE INTOLERANT TO CONVENTIONAL THERAPIES BUT HAVE NOT FAILED BIOLOGIC THERAPY (M14-433)
AbbVie	A PHASE 3 MULTICENTER, OPEN-LABEL EXTENSION (OLE) STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF ABT-494 IN SUBJECTS WITH ULCERATIVE COLITIS (M14-533)
AbbVie	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UPADACITINIB (ABT-494) IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (M14-675)
AbbVie	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY TO ASSESS THE EFFICACY AND SAFETY OF RISANKIZUMAB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO FAILED PRIOR BIOLOGIC TREATMENT (M15-991)
AbbVie	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 52-WEEK MAINTENANCE AND AN OPEN-LABEL EXTENSION STUDY OF THE EFFICACY AND SAFETY OF RISANKIZUMAB IN SUBJECTS WITH CROHN'S DISEASE WHO RESPONDED TO INDUCTION TREATMENT IN M16-006 OR M15-991 (M16-000)
AbbVie	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 52-WEEK MAINTENANCE AND AN OPEN-LABEL EXTENSION STUDY OF THE EFFICACY AND SAFETY OF RISANKIZUMAB IN SUBJECTS WITH ULCERATIVE COLITIS WHO RESPONDED TO INDUCTION TREATMENT IN M16-067 OR M16-065 (M16-066)

Celgene Bristol-Meyers Squibb	INDUCTION STUDY #1 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN¿S DISEASE (RPC01-3201)
Celgene Bristol-Meyers Squibb	RPCOL-3203: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
Celgene Bristol-Meyers Squibb	RPC01-3204: A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY OF ORAL OZANIMOD FOR MODERATELY TO SEVERELY ACTIVE CROHN¿S DISEASE
Eli Lilly and Co.	PROTOCOL I6T-MC-AMAN A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 1
Genentech Inc.	A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF UTTR1147A COMPARED WITH PLACEBO AND COMPARED WITH VEDOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Pfizer Inc.	A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND CHRONIC THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS